<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990675</url>
  </required_header>
  <id_info>
    <org_study_id>Pancreatic cancer organoids</org_study_id>
    <nct_id>NCT03990675</nct_id>
  </id_info>
  <brief_title>Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids</brief_title>
  <official_title>Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t M체nchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universit채t M체nchen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer.
      Despite advances in the understanding of the mechanisms underlying PDAC pathogenesis, the
      impact on patient benefit is lagging. As a result, new model systems are being developed and
      used to fill this gap with the hope of translation into improved diagnostics and
      therapeutics.

      Organoids represent a powerful tool for research with the capacity to be applied to many key
      aspects of pancreatic tissue pathology.

      3D organoids can be generated from endoscopic fine-needle aspiration or fine needle biopsy
      samples. In this study, we will evaluate and compare the growth rate of pancreatic cancer
      patient-derived organoids generated from matched fine needle Aspirations (FNA) and fine
      needle biopsies (FNB).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth rate</measure>
    <time_frame>4 days</time_frame>
    <description>Organoid growth will be determined using bi-weekly measurements by phase-contrast microscopy calculating the total organoid area as well as individual organoid size. In addition, growth rates will be determined using the cell glow assay (Promega) over a time-course of 4 days. Furthermore, the mean passaging time will be calculated after 5 passages.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>FNA, FNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FNA, FNB</intervention_name>
    <description>Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy</description>
    <arm_group_label>FNA, FNB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with indication for EUS-guided FNA or FNB of a suspected pancreatic
             malignancy

        Exclusion Criteria:

          -  &lt; 18 years

          -  patients unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christoph Schlag, MD</last_name>
    <phone>+49 89 4140 9357</phone>
    <email>christoph.schlag@mri.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maximilian Reichert, MD</last_name>
    <phone>+49 89 4140 9454</phone>
    <email>maximilian.reichert@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Medical Department, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schlag, MD</last_name>
      <phone>+49 89 4140 9357</phone>
      <email>christoph.schlag@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Johannes R Wiessner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian Reichert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Schlag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

